Pfizer CEO open to big buyout deals

In an interview with the Financial Times, Pfizer CEO Jeff Kindler said the company is willing to acquire a large rival drugs company to improve its financial health, in a move that could trigger a fresh round of mergers within the sector. "The real goal is to grow revenues...We are open to opportunities and constantly looking at those which are big, small and in between," Kindler said in an interview. Pfizer is bracing itself to the expiration of Lipitor's patent protection in 2011; a major deal could help the company fill the $13-billion-a-year void the drug's patent expiration will cause. Report

Suggested Articles

Bayer's new Vitrakvi for tumors with NTRK gene fusions is meeting skepticism in England and Germany, where cost watchdogs on Friday rejected it.

Hengrui's Sun Piaoyang is stepping down as chairman, but he'll retain control of the pharma major he's headed for 30 years—and made a fortune…

Astellas tapped Adaptimmune to develop T-cell therapies. Ireland hit Takeda with an unexpected Shire tax bill. PD-1 med Tyvyt hit its goal in NSCLC.